News & Updates
Filter by Specialty:

Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
A study suggests that in choosing CDK4/6 inhibitors (palbociclib and abemaciclib) for patients with hormone receptor-positive, HER2-negative metastatic/recurrent breast cancer, considerations must be made based on the tolerability and manageability of adverse events (AEs).
Palbociclib vs abemaciclib: How to choose the right treatment for breast cancer patients
01 Dec 2024
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024
Presence of mVI/S predicts HCC recurrence after liver resection
Microvascular invasion and/or satellitosis (mVI/S) is independently associated with aggressive recurrence and mortality in hepatocellular carcinoma (HCC) patients treated with liver resection (LR), a recent study has shown.
Presence of mVI/S predicts HCC recurrence after liver resection
26 Nov 2024
Is ChatGPT ready to give CRC screening recommendations?
The performance of ChatGPT in determining appropriate colorectal cancer (CRC) screening recommendations is relatively poor, with inconsistent responses in several questions, reports a study.